Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies

Wouters, Olivier J. ORCID: 0000-0002-2514-476X, Naci, Huseyin ORCID: 0000-0002-7192-5751 and Papanicolas, Irene ORCID: 0000-0002-8000-3185 (2024) Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies. Journal of American Medical Association: Internal Medicine, 184 (3). 328 - 330. ISSN 2168-6106

Text (Availability and Coverage of New Drugs in 6 High-Income Countries with Health Technology Assessment Bodies) - Accepted Version Download (698kB)

• Author
• Author
• Author
• Scopus publication

Abstract

Most high-income countries except the US rely on health technology assessment (HTA) to ensure that prices paid for new medicines reflect the value they provide.1,2 Health technology assessment bodies assess the relative clinical or economic impact of new drugs to guide pricing and coverage decisions. These assessments usually occur after marketing authorization by a medicines regulatory body (eg, European Medicines Agency), and patients may have little or no access to therapies not assessed favorably by HTA bodies.

Item Type:	Article
Official URL:	https://jamanetwork.com/journals/jamainternalmedic...
Additional Information:	© 2024 American Medical Association
Divisions:	Health Policy
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine T Technology
Date Deposited:	20 Dec 2023 12:15
Last Modified:	15 Nov 2024 02:09
URI:	http://eprints.lse.ac.uk/id/eprint/121119

Actions (login required)

View Item